Literature DB >> 19004572

Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.

Barbara A Jereczek-Fossa1, Dario Zerini, Andrea Vavassori, Cristiana Fodor, Luigi Santoro, Antonio Minissale, Raffaella Cambria, Federica Cattani, Cristina Garibaldi, Flavia Serafini, Victor Deliu Matei, Ottavio de Cobelli, Roberto Orecchia.   

Abstract

PURPOSE: To evaluate the outcome of postoperative radiotherapy (PORT) and salvage RT (SART) using a three-dimensional conformal two-dynamic arc (3D-ART) or 3D six-field technique in 431 prostate cancer patients. METHODS AND MATERIALS: Of the 431 patients, 258 underwent PORT (started <6 months after radical prostatectomy) and 173 underwent SART because of biochemical failure after radical prostatectomy. The median patient age, preoperative prostate-specific antigen level, and Gleason score was 66 years, 9.4 ng/mL, and 7, respectively. The median radiation dose was 70 Gy in 35 fractions for both PORT and SART. The 3D six-field and 3D-ART techniques were used in 25.1% and 74.9% of patients, respectively. Biochemical failure was defined as a post-RT prostate-specific antigen nadir plus 0.1 ng/mL.
RESULTS: Acute toxicity included rectal events (PORT, 44.2% and 0.8% Grade 1-2 and Grade 3, respectively; SART, 42.2% and 1.2% Grade 1-2 and Grade 3, respectively) and urinary events (PORT, 51.2% and 2.3% Grade 1-2 and Grade 3-4, respectively; SART, 37.6% and 0% Grade 1-2 and Grade 3, respectively). Late toxicity also included rectal events (PORT, 14.7% and 0.8% Grade 1-2 and Grade 3-4, respectively; SART, 15.0% and 0.6% Grade 1-2 and Grade 3, respectively) and urinary events (PORT, 28.3% and 3.7% Grade 1-2 and Grade 3-4, respectively; SART, 19.3% and 0.6% Grade 1-2 and Grade 3, respectively). After a median follow-up of 48 months, failure-free survival, including biochemical and clinical failure, was significantly longer in the PORT patients (79.8% vs. 60.5%, p < 0.0001). Multivariate analysis showed that a prostate-specific antigen level postoperatively but before RT of >/=0.2 ng/mL (p < 0.001), Gleason score >6 (p = 0.025) and use of preoperative androgen deprivation (p = 0.002) correlated significantly with shorter failure-free survival. Multivariate analysis showed that PORT and the 3D-ART technique correlated with greater late urinary toxicity.
CONCLUSION: PORT and early referral for SART offer better disease control after radical prostatectomy. The greater urinary toxicity occurring after PORT and 3D-ART requires further investigation to improve the therapeutic index.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004572     DOI: 10.1016/j.ijrobp.2008.07.057

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  [Organ-limited prostate cancer with positive resection margins. Importance of adjuvant radiation therapy].

Authors:  D Porres; D Pfister; B Brehmer; A Heidenreich
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

2.  [Tumour recurrence].

Authors:  O W Hakenberg; F Sedlmayer
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

3.  No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy.

Authors:  Barbara A Jereczek-Fossa; Delia Ciardo; Silvia Ferrario; Piero Fossati; Giuseppe Fanetti; Dario Zerini; Davide Zannoni; Cristiana Fodor; Marianna A Gerardi; Alessia Surgo; Matteo Muto; Raffaella Cambria; Ottavio De Cobelli; Roberto Orecchia
Journal:  Br J Radiol       Date:  2016-04-25       Impact factor: 3.039

4.  Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.

Authors:  A Hervás; A Gómez-Caamaño; M Casaña; A Gómez-Iturriaga; J Pastor; J Jove; J L Mengual; C Gónzalez-San Segundo; J Muñoz
Journal:  Clin Transl Oncol       Date:  2017-06-30       Impact factor: 3.405

5.  Results of radical prostatectomy in newly diagnosed prostate cancer: long-term survival rates in locally advanced and high-risk cancers.

Authors:  Hendrik Isbarn; Hartwig Huland; Markus Graefen
Journal:  Dtsch Arztebl Int       Date:  2013-07-22       Impact factor: 5.594

6.  Continuous prostate-specific antigen rise despite salvage radiotherapy following radical prostatectomy: Pattern of clinical relapse and predictive factors.

Authors:  Carsten Nieder; Kirsten Marienhagen; Roy M Kristensen; Torbjørn Sørbye; Lars Hoem
Journal:  Oncol Lett       Date:  2015-12-04       Impact factor: 2.967

Review 7.  Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.

Authors:  Robert T Dess; Todd M Morgan; Paul L Nguyen; Rohit Mehra; Howard M Sandler; Felix Y Feng; Daniel E Spratt
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

8.  Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer: a comparison between dose-volume constraints and NTCP use.

Authors:  Raffaella Cambria; Barbara A Jereczek-Fossa; Federica Cattani; Cristina Garibaldi; Dario Zerini; Cristiana Fodor; Flavia Serafini; Guido Pedroli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

9.  Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml.

Authors:  Rei Umezawa; Hisanori Ariga; Yoshihiro Ogawa; Keiichi Jingu; Haruo Matsushita; Ken Takeda; Keisuke Fujimoto; Toru Sakayauchi; Toshiyuki Sugawara; Masaki Kubozono; Kakutaro Narazaki; Eiji Shimizu; Yoshihiro Takai; Shogo Yamada
Journal:  Radiat Oncol       Date:  2011-11-05       Impact factor: 3.481

Review 10.  Adjuvant and salvage radiotherapy after prostatectomy: a systematic review and meta-analysis.

Authors:  Changhao Chen; Tianxin Lin; Yu Zhou; Doudou Li; Kewei Xu; Zhihua Li; Xinxiang Fan; Guangzheng Zhong; Wang He; Xu Chen; Xianyin He; Jian Huang
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.